NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: St. Olavs Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Conditions

• Myeloma Multiple
• Plasma Cell Leukemia
• AL Amyloidosis

Interventions

Type	Name	Description
DRUG	Teclistamab	Real-world use and dosing
DRUG	Elranatamab	Real-world use and dosing
BIOLOGICAL	Ciltacabtagene Autoleucel	Real-world use.
DRUG	Talquetamab	Real-world use and dosing
BIOLOGICAL	Idecabtagene vicleucel	Real-world use and dosing

Timeline

• Start date: 2025-01-15
• Primary completion: 2029-01-01
• Completion: 2037-12-01
• First posted: 2025-03-03
• Last updated: 2025-03-03

Locations

23 sites across 1 country: Norway